IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-e

IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-expressing advanced solid tumors Immunome - phase 1 trial to evaluate safety and preliminary activity of im-3050